Open access
Sep 2026
A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
Background Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor t...
O. Kilim, O. Pipek, Z. Sztupinszki et al.
· Immuno-Oncology Technology · 0 citations